- Home
- RAND vs BTAI Comparison
RAND vs BTAI Comparison
Compare RAND & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- BTAI
- Stock Information
- Founded
- RAND 1969
- BTAI 2017
- Country
- RAND United States
- BTAI United States
- Employees
- RAND N/A
- BTAI N/A
- Industry
- RAND Finance: Consumer Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- BTAI Health Care
- Exchange
- RAND Nasdaq
- BTAI Nasdaq
- Market Cap
- RAND 44.7M
- BTAI 52.7M
- IPO Year
- RAND N/A
- BTAI 2018
- Fundamental
- Price
- RAND $14.37
- BTAI $2.48
- Analyst Decision
- RAND
- BTAI Buy
- Analyst Count
- RAND 0
- BTAI 5
- Target Price
- RAND N/A
- BTAI $32.80
- AVG Volume (30 Days)
- RAND 4.0K
- BTAI 1.6M
- Earning Date
- RAND 11-05-2025
- BTAI 11-13-2025
- Dividend Yield
- RAND 11.24%
- BTAI N/A
- EPS Growth
- RAND N/A
- BTAI N/A
- EPS
- RAND N/A
- BTAI N/A
- Revenue
- RAND $7,966,118.00
- BTAI $868,000.00
- Revenue This Year
- RAND N/A
- BTAI N/A
- Revenue Next Year
- RAND N/A
- BTAI $614.78
- P/E Ratio
- RAND N/A
- BTAI N/A
- Revenue Growth
- RAND 1.16
- BTAI N/A
- 52 Week Low
- RAND $13.82
- BTAI $1.17
- 52 Week High
- RAND $31.89
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- RAND 41.83
- BTAI 38.09
- Support Level
- RAND $14.27
- BTAI $2.47
- Resistance Level
- RAND $15.22
- BTAI $2.70
- Average True Range (ATR)
- RAND 0.45
- BTAI 0.21
- MACD
- RAND 0.03
- BTAI -0.00
- Stochastic Oscillator
- RAND 10.21
- BTAI 9.74
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.